Clin2
NCT06387121Likely a fitRecruiting

Low-dose chemo plus immune drugs for new B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Treatments studied

Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.

This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
53 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are newly diagnosed with a type of leukemia called B-cell acute lymphoblastic leukemia that does not have the Philadelphia chromosome (Ph-negative).
  • Your leukemia cells must have a protein called CD22 on their surface (your doctor can check this).
  • You must be 18 years old or older.
  • You are expected to live at least 3 more months.
  • You are willing to use effective birth control if you or your partner can become pregnant.
  • You do not have other serious health problems like severe infection, certain liver diseases, or heart rhythm issues.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06481241Recruiting
Chemotherapy plus CAR-T for newly diagnosed Ph- B-ALL

This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.

Tianjin
NCT07493161Recruiting
Chemo with targeted therapy for new Ph+ ALL

This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.

Tianjin, Tianjin Municipality
NCT07495631Recruiting
Chemo + venetoclax + immunotherapy for adult ALL

This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.

Tianjin, Tianjin Municipality
NCT07643103Not yet recruiting· Phase 2
New Treatment for Adult B-Cell Acute Lymphoblastic Leukemia

This trial tests a combination of targeted immunotherapy (a drug that helps your immune system fight cancer) plus low-dose chemotherapy for adults newly diagnosed with a specific type of blood cancer called Ph-negative B-ALL. The goal is to see if this approach can work better than standard treatments while being easier on your body.

NCT06554626Recruiting· Phase 2
Study of blinatumomab and venetoclax followed by inotuzumab for B-ALL

This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.

Hangzhou, Zhejiang
NCT02877303Recruiting· Phase 2
Frontline drug treatment for newly diagnosed B-cell leukemia

This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.

Houston, Texas

Hear when a new Precursor Cell Lymphoblastic Leukemia-Lymphoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.